2月27日，云顶新耀宣布公司原研产品布地奈德肠溶胶囊（耐赋康®）专利维权取得关键进展。广州知识产权法院已于 2026年2月26日作出民事裁定书，全面支持公司提出的诉前行为保全申请，并责令相关仿制药企业立即停止侵权行为 并停止挂网，该裁定自作出之日起立即执行。 （云顶新耀公众号） ...

广州知识产权法院已于2026年2月26日作出民事裁定书，全面支持公司提出的诉前行为保全申请，并责 令相关仿制药企业立即停止侵权行为并停止挂网，该裁定自作出之日起立即执行。公司对法院的公正裁 定表示欢迎。 公司将持续依法维护知识产权，促进创新疗法惠及更多患者。 云顶新耀(01952.HK)是一家专注于创新药开发、制造和商业化的生物制药公司，今日宣布公司原研产品 布地奈德肠溶胶囊(耐赋康®)专利维权取得关键进展。 ...

Core Viewpoint - The company, Genting New Year (01952.HK), has noted the approval of a generic version of its patented product Budesonide Enteric Capsules (耐赋康®) by the National Medical Products Administration of China, while emphasizing the protection of its original product under a valid patent until May 7, 2029 [1] Group 1 - The company’s original product,耐赋康®, is protected by patent ZL200980127272.5, which is currently valid [1] - The patent rights will expire on May 7, 2029, and the company has registered relevant patent information on the Chinese drug patent information registration platform [1] - According to Chinese patent law, any entity or individual must obtain legal permission from the company before manufacturing, using, or selling products that fall under the patent protection before its expiration [1] Group 2 - The company reserves the right to take legal action against any infringement of the patent rights or violations of commitments made by generic drug applicants [1] - Generic drug applicants must adhere to their commitments if they submit a "Category 3 Declaration," promising not to market the drug before the patent expires [1]

Core Viewpoint - The company has noted the approval of a generic version of its product Budesonide Enteric-Coated Capsules (耐赋康®) by the National Medical Products Administration of China, while emphasizing the protection of its original product under a valid patent until May 7, 2029 [1] Group 1 - The company holds a patent (ZL200980127272.5) for its original product in China, which is currently valid [1] - The patent information has been registered with the Chinese drug patent information registration platform [1] - According to Chinese patent law, any entity or individual must not manufacture, use, promise to sell, or import products that fall under the patent protection without the company's legal permission before the patent expires [1] Group 2 - The company reserves the right to take legal action against any infringement of the patent or violations of commitments made by generic applicants [1] - Generic applicants must adhere to their commitments if they submit a "Category 3 Declaration," promising not to market the drug before the patent expiration [1]

Group 1 - The board of directors of the company noted the approval of a generic version of its patented product Budesonide Enteric-Coated Capsules (耐赋康®) by the National Medical Products Administration of China [1] - The original product is protected by patent ZL200980127272.5, which is valid until May 7, 2029, and the company has registered this information on the Chinese drug patent information registration platform [1] - According to Chinese patent law, any entity or individual must not manufacture, use, promise to sell, or import products within the patent protection scope without the company's legal permission before the patent expires, or it will constitute patent infringement [1] Group 2 - The company is committed to introducing breakthrough therapies to China to meet urgent medical needs, emphasizing the importance of a robust patent protection system and effective regulations for the sustainable accessibility of innovative drugs [2] - The environment for intellectual property protection in China's pharmaceutical industry has been continuously optimized, providing strong support for pharmaceutical innovation and healthy industry development [2] - The company will continue to collaborate with various parties to respect and uphold intellectual property rights, adhere to relevant laws and regulations, and foster a fair competitive environment to promote the ongoing development and accessibility of innovative drugs for the benefit of Chinese patients [2]